Exploring Esa Treatment Outcomes In Lower-Risk Mds: Expert Perspectives

Exploring ESA Treatment Outcomes in Lower-Risk MDS: Expert Perspectives

Blood Cancers Today

ESAs-Only MDS Management: Does the Real-World Experience Differ from Clinical Trials?

Blood Cancers Today

Understanding Lower Risk MDS What Are My Options

Luspatercept for the treatment of patients with lower-risk MDS and ESA failure

VJHemOnc – Video Journal of Hematology & HemOnc

Real-world treatment patterns of patients with low-risk MDS reinitiating ESAs

VJHemOnc – Video Journal of Hematology & HemOnc

What to Know About Optimal Luspatercept Use in Lower-Risk MDS

Blood Cancers Today

ESAs for the management of lower-risk MDS

VJHemOnc – Video Journal of Hematology & HemOnc

Novel Treatment Strategies in Low-Risk MDS: Challenges and Emerging Therapies

The impact of ESAs in lower-risk MDS

VJHemOnc – Video Journal of Hematology & HemOnc

The COMMANDS study: luspatercept versus epoetin alfa for ESA-naïve lower-risk MDS-associated anemia

VJHemOnc – Video Journal of Hematology & HemOnc

Approaching ESA failure in patients with lower-risk MDS

VJHemOnc – Video Journal of Hematology & HemOnc

Management of Lower-risk MDS without Del5q and Refractory to ESAs

Improving the treatment of low-risk MDS: luspatercept, treatment sequencing & disease classification

VJHemOnc – Video Journal of Hematology & HemOnc

Novel Treatment Strategies in Low-Risk MDS: Q&A

How is lower-risk MDS treated?

Navigating ESA Failure in MDS

Blood Cancers Today

The role of ESAs agents in low-risk MDS

VJHemOnc – Video Journal of Hematology & HemOnc

Current and emerging treatment options for LR-MDS-associated anemia following ESA failure

VJHemOnc – Video Journal of Hematology & HemOnc

Key highlights in MDS: treating lower-risk & higher-risk disease, trial updates, and more

VJHemOnc – Video Journal of Hematology & HemOnc